Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.83 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.83 |
| ▸ | MLNR | O43193 | 1/20 | 0.83 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | GAA | P10253 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | DRD2 | P14416 | 1/20 | 0.83 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | HTR2A | P28223 | 1/20 | 0.83 |
| ▸ | HTR2C | P28335 | 1/20 | 0.83 |
| ▸ | MC4R | P32245 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL308488 | 0.94 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2120068 | 0.94 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3896385 | 0.94 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3335 | 0.94 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL4573554 | 0.93 | SLC6A2 (0.85) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2109339 | 0.92 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL28851559 | 0.92 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL28851600 | 0.92 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL991500 | 0.91 | SLC6A2 (0.95) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 0.91 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513439-B2 | Antidepressant oral pharmaceutical compositions | WOCKHARDT LIMITED (IN) | 2013-08-20 | — | — | US | disclosed |
| US-8455667-B2 | Duloxetine compositions in the form of a powder for suspension in a liquid | WOCKHARDT LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20120202869-A1 | Antidepressant Oral Pharmaceutical Compositions | WOCKHARDT LTD. (IN) | 2012-08-09 | — | — | US | disclosed |
| US-20120196917-A1 | Antidepressant Oral Liquid Compositions | WOCKHARDT LTD. (IN) | 2012-08-02 | — | — | US | disclosed |
| US-8153824-B2 | Antidepressant oral liquid compositions | The Wockhardt Company (IN) | 2012-04-10 | — | — | US | disclosed |
| US-8093408-B2 | Antidepressant oral pharmaceutical compositions | The Company Wockhardt (IN) | 2012-01-10 | — | — | US | disclosed |
| US-20110052647-A1 | Antidepressant Oral Pharmaceutical Compositions | WOCKHARDT (IN) | 2011-03-03 | — | — | US | disclosed |
| US-20070004795-A1 | Antidepressant oral pharmaceutical compositions | NANOCRYSTAL ASIA INC. (TW) | 2007-01-04 | — | — | US | disclosed |
| US-20060165776-A1 | Antidepressant oral pharmaceutical compositions | COMPANY WOCKHARDT, THE (IN) | 2006-07-27 | — | — | US | disclosed |
| US-20060079569-A1 | Antidepressant oral liquid compositions | COMPANY WOCKHARDT, THE (IN) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165776-A1 | Antidepressant oral pharmaceutical compositions | SI, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885SLC6A3 10/4885 |
| US-20070004795-A1 | Antidepressant oral pharmaceutical compositions | SLC6A4, SLC5A1, SLC5A2 | SLC6A2 6/4885SLC6A4 1/4885SLC6A3 11/4885 |
| US-20060079569-A1 | Antidepressant oral liquid compositions | SLC6A4, SLC5A1, OPRL1 | SLC6A2 5/4885SLC6A4 1/4885SLC6A3 18/4885 |
| US-20120196917-A1 | Antidepressant Oral Liquid Compositions | SLC6A4, SLC5A1, OPRL1 | SLC6A2 5/4885SLC6A4 1/4885SLC6A3 18/4885 |
| US-20120202869-A1 | Antidepressant Oral Pharmaceutical Compositions | SLC6A4, SLC5A1, SLC5A2 | SLC6A2 6/4885SLC6A4 1/4885SLC6A3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.